Form 4: Rapport Therapeutics Director Receives Stock Options

Director John Maraganore was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director John Maraganore acquired 15,200 stock options in Rapport Therapeutics, Inc. (RAPP).
• The options have an exercise price of $35.21 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced leadership for clinical-stage companies.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of a one-year cliff vesting period aligns with common corporate governance practices for board members.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 10, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Options, Director Compensation